Clinical Value of Core Length in Contemporary Multicore Prostate Biopsy

Lee, Sangchul; Jeong, Seong Jin; Hwang, Sung Il; Hong, Sung Kyu; Lee, Hak Jong; Byun, Seok Soo; Choe, Gheeyoung

doi:10.1371/journal.pone.0123704

Cited by 5 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men with larger prostates [17][18][19] We also found that all biopsy CLs (TCL, ACL, and MCL) were positively correlated with PV. Similarly, Lee et al [13] found a significant positive correlation between their CL (no description given) and PV. Additionally, we found that percentage of PCa decreased and all studied parameters (MCL, ACL, and TCL) increased steadily with increasing PV categories in our study.…”

Section: Discussionmentioning

confidence: 80%

“…Similarly, although Ficarra et al [12] did not give data for TCL, they compared mean lengths of the benign and malignant biopsy cores from 14 separate sites in their perineal prostate biopsy cohort, and did not find any significant difference. Recently, Lee et al [13] published the analyses of their data on 3,479 patients who had had ≥12-core TRUS-guided prostate biopsies. They found no significant difference between patients with PCa and without PCa regarding mean CL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Longer biopsy cores do not increase prostate cancer detection rate: A large-scale cohort study refuting cut-off values indicated in the literature

Yılmaz

Yavuz²,

Üstüner³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: Only a few papers in the literature aimed to evaluate biopsy core lengths. Additionally, studies evaluated the core length with different approaches. We aimed to determine whether prostate cancer (PCa) detection is affected from core lengths according to three different approaches in a large standard cohort and compare our cut-off values with the published cut-offs. Material and methods:We retrospectively analyzed 1,523 initial consecutive transrectal ultrasound-guided 12-core prostate biopsies. Biopsies were evaluated with respect to total core length (total length of each patients' core) average core length (total core length divided by total number of cores in each patient), and mean core length (mean length of all cores pooled), and compared our cut-off values with the published cut-offs. The prostate volumes were categorized into four groups (<30, 30-59.99, 60-119.99, ≥120 cm 3 ) and PCa detection rates in these categories were examined.Results: PCa was found in 41.5% patients. There was no difference between benign and malignant mean core lengths of the pooled cores (p>0.05). Total core length and average core length were not significantly associated with PCa in multivariate logistic regression analyses (p>0.05). The core lengths (mean, average and total core lengths) increased (p<0.001) and PCa rates decreased (p<0.001) steadily with increasing prostate volume categories. PCa percentages decreased in all categories above the utilized cut-offs for mean (p>0.05), average (p<0.05), and total core lengths (p>0.05). Conclusion:There was no difference between mean core lengths of benign and malignant cores. Total core length and average core length were not significantly associated with PCa. Contrary to the cut-offs used for mean and average core lengths in the published studies, PCa rates decrease as these core lengths increase. Larger studies are necessary for the determination and acceptance of accurate cut-offs.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Longer biopsy cores do not increase prostate cancer detection rate: A large-scale cohort study refuting cut-off values indicated in the literature

Yılmaz

Yavuz²,

Üstüner³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Although many studies have been published on the number and localization of the cores in the literature, very few have investigated the effect of core length as an indicator of the quality of prostate biopsy (13). This may be affected by many factors, including the length of the core obtained in a biopsy, the biopsy technique performed by the urologist, the diameter of the biopsy needle, the rigidity of the site the sample obtained, and the method of sample collection (14). Although there are studies Figure 1.…”

Section: Discussionmentioning

confidence: 99%

“…Lee et al (14) reported that 3479 patients with a PSA level of <10 ng/mL were evaluated after multi-core prostate biopsy, and the mean core length for patients with and without cancer was the same (16.1 mm), and hence, they claimed that PCa detection rate was not affected by the core length. Similar to this study and that by Ficarra et al (18), we did not observe a correlation between mean core length and the cancer detection rate in our study.…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Core Lenght in Saturation Prostate Biopsy

Yücel¹,

Budak²

2018

jus

View full text Add to dashboard Cite

Objective: To investigate the effect of core length on cancer detection in saturation prostate biopsy. We hypothesized that increasing mean and total core length in saturation prostate biopsy may allow more tissue sampling, thus, may increase the prostate cancer detection rate. Materials and Methods: We retrospectively analyzed medical records of 145 patients who underwent 24-core transrectal ultrasound-guided saturation biopsy at our institution. We evaluated the clinopathological factors, including age, prostate specific antigen (PSA), prostate volume, mean core length and the total biopsy core length. The patients were divided into 3 groups according to their total biopsy core length; group 1: <20 cm, group 2: 20-30 cm and group 3: >30 cm. These groups were compared according to age, PSA value, prostate volume and cancer detection rate. Results: The mean age, core length and total core length were 62.4±7.0 years, 10.91±1.8 mm, and 26.2±4.7 cm, respectively. The overall cancer detection rate was 33.8%. There was no statistically significant difference in mean core length and total core length between patients diagnosed with prostate cancer and those without it. The cancer detection rates in group 1, 2 and 3 were 25%, 37.4% and 23.1%, respectively. When these 3 groups were compared with each other, group 2 had a statistically significantly higher cancer detection rate relative to group 1 (p=0.001). Multivariate analysis showed no statistically difference in cancer detection rate between the groups (p=0.302). Conclusion: Mean and total core length may not have any significant effect on prostate cancer detection in patients undergoing saturation prostate biopsy.

show abstract

“…All TRUS-guided biopsies were performed with a Logiq E9 US machine (GE Healthcare, USA) equipped with a 5-9 MHz multifrequency endocavitary probe by the same uroradiologist who had conducted the image fusion [24]. An 18-gauge, 20 cm automatic cutting needle and an automated biopsy gun (ACECUT, TSK Laboratory, Japan) were used [24,25].…”

Section: Trus/mri Fusion Biopsymentioning

confidence: 99%

Comparing Prostate Imaging‐Reporting and Data System Version 2 (PI‐RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging

Kim

Lee

Hwang

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Objectives. To evaluate the clinicopathological differences between Prostate Imaging-Reporting and Data System (PI-RADS) version 2 (v2) category 1 and 2 groups. Materials and Methods. We retrospectively reviewed our two institutional clinical databases: (1) transrectal ultrasound (TRUS)/magnetic resonance imaging (MRI) fusion biopsy cohort (n=706) and (2) radical prostatectomy (RP) cohort (n=1403). Subsequently, we performed comparative analyses between PI-RADSv2 category 1 and 2 groups. Clinically significant prostate cancer (csPCa) was defined as the presence of Gleason score GS≥3+4 in a single biopsy core, and adverse pathology (AP) was defined as high-grade (primary Gleason pattern 4 or any pattern 5) and/or non-organ-confined disease (pT3/N1). We also performed multivariate logistic regression analyses for AP. Results. In the TRUS/MRI fusion biopsy cohort, no significant differences in detection rates of all cancer (18.2% vs. 29.0%, respectively, P=0.730) or csPCa (9.1% vs. 9.9%, respectively, P=0.692) were observed between PI-RADSv2 category 1 and 2 groups. There were no significant differences in pathologic outcomes including Gleason score (≥4+3, 21.2% vs. 29.9%, respectively, P=0.420) or detection rate of AP (27.3% vs. 33.8%, respectively, P=0.561) between the two groups in the RP cohort either. PI-RADSv2 category 1 or 2 had no significant association with AP, even in univariate analysis (P=0.299). Conclusions. PI-RADSv2 categories 1 and 2 had similar performance to predict clinicopathological outcomes. Consequently, these two categories may be unified into a single category. Negative mpMRI does not guarantee the absence of AP, as with csPCa.

show abstract

Clinical Value of Core Length in Contemporary Multicore Prostate Biopsy

Cited by 5 publications

References 21 publications

Longer biopsy cores do not increase prostate cancer detection rate: A large-scale cohort study refuting cut-off values indicated in the literature

Longer biopsy cores do not increase prostate cancer detection rate: A large-scale cohort study refuting cut-off values indicated in the literature

Clinical Value of Core Lenght in Saturation Prostate Biopsy

Comparing Prostate Imaging‐Reporting and Data System Version 2 (PI‐RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging

Contact Info

Product

Resources

About